Severe Eosinophilic Asthma (SEA)
Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older.
Denne nettleseren støttes ikke lenger.
For å gi deg best mulig opplevelse, ber vi deg bytte til en annen nettleser:
Anoro Ellipta 20 mcg
har blitt lagt til din handelkurv.
Nucala is the anti-IL-5 therapy that is approved for the treatment of 4 eosinophilic diseases.1
Nucala is a trademark of the GSK group of companies
PM-NO-MPL-WCNT-230001 June 2023